Portage Biotech, NCI, Stimunity enter cooperative R&D agreement to develop STING agonists and anti-RAGE agents for cancer vaccines

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Portage Biotech Inc., NCI, and Stimunity entered a Cooperative Research and Development Agreement, under which they will collaborate with NCI’s Center for Cancer Research to advance preclinical and potential clinical development of STING agonists and anti-Receptor for Advanced Glycation End products (RAGE) agents to enhance the efficacy of cancer vaccines developed in the NCI CCR Vaccine Branch. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Growing up in inner-city Detroit, Otis Brawley had a thriving community made up of his parents, Jesuit priests, friends, and neighbors encouraging him that he could do anything he put his mind to. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login